Traders sold shares of Celgene Corp. (NASDAQ:CELG) on strength during trading hours on Wednesday. $161.98 million flowed into the stock on the tick-up and $202.02 million flowed out of the stock on the tick-down, for a money net flow of $40.04 million out of the stock. Of all equities tracked, Celgene Corp. had the 0th highest net out-flow for the day. Celgene Corp. traded up $1.85 for the day and closed at $116.14

CELG has been the subject of a number of research reports. Leerink Swann reiterated a “market perform” rating on shares of Celgene Corp. in a research report on Monday, May 2nd. Cantor Fitzgerald reiterated a “buy” rating on shares of Celgene Corp. in a research report on Wednesday, June 8th. BTIG Research reiterated a “buy” rating and issued a $140.00 price objective on shares of Celgene Corp. in a research report on Tuesday, May 24th. RBC Capital Markets reiterated a “buy” rating on shares of Celgene Corp. in a research report on Tuesday, July 26th. Finally, Jefferies Group reiterated a “buy” rating and issued a $138.00 price objective on shares of Celgene Corp. in a research report on Tuesday, July 26th. Five analysts have rated the stock with a hold rating and twenty-three have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $137.33.

The stock has a market cap of $90.02 billion and a PE ratio of 49.09. The company’s 50-day moving average price is $103.54 and its 200 day moving average price is $103.28.

Celgene Corp. (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.05. During the same period last year, the business posted $1.23 EPS. The firm earned $2.74 billion during the quarter, compared to analyst estimates of $2.70 billion. The company’s revenue was up 20.9% on a year-over-year basis. On average, equities research analysts predict that Celgene Corp. will post $5.76 earnings per share for the current year.

In other news, insider Robert J. Hugin sold 75,000 shares of the firm’s stock in a transaction that occurred on Monday, June 20th. The stock was sold at an average price of $100.16, for a total value of $7,512,000.00. Following the transaction, the insider now owns 1,122,201 shares in the company, valued at $112,399,652.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Robert J. Hugin sold 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $110.00, for a total value of $11,000,000.00. Following the completion of the transaction, the insider now owns 1,022,201 shares in the company, valued at approximately $112,442,110. The disclosure for this sale can be found here.

Other hedge funds and institutional investors recently bought and sold shares of the company. Genesee Valley Trust Co. raised its position in Celgene Corp. by 4.2% in the fourth quarter. Genesee Valley Trust Co. now owns 8,820 shares of the biopharmaceutical company’s stock worth $1,056,000 after buying an additional 359 shares in the last quarter. Investment Management of Virginia LLC raised its position in Celgene Corp. by 63.0% in the fourth quarter. Investment Management of Virginia LLC now owns 9,043 shares of the biopharmaceutical company’s stock worth $1,083,000 after buying an additional 3,495 shares in the last quarter. NBT Bank N A NY raised its position in Celgene Corp. by 0.3% in the fourth quarter. NBT Bank N A NY now owns 9,248 shares of the biopharmaceutical company’s stock worth $1,107,000 after buying an additional 30 shares in the last quarter. Greenwood Capital Associates LLC raised its position in Celgene Corp. by 5.2% in the fourth quarter. Greenwood Capital Associates LLC now owns 10,212 shares of the biopharmaceutical company’s stock worth $1,223,000 after buying an additional 505 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. bought a new position in Celgene Corp. during the fourth quarter worth $1,365,000.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.